{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:31:41Z","timestamp":1794270701225,"version":"4.9.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Kakihara Foundation"},{"DOI":"10.13039\/100018289","name":"The Shinnihon Foundation of Advanced Medical Treatment Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018289","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007206","name":"Kaibara Morikazu Medical Science Promotion Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007206","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["25lk0221207h0001"],"award-info":[{"award-number":["25lk0221207h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["25lk0221207h0001"],"award-info":[{"award-number":["25lk0221207h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-025-02493-6","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:50:54Z","timestamp":1761659454000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation in EGFR-mutant non\u2013small cell lung cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Ritsu","family":"Ibusuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Iwama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Shimauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromu","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Mizusaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yui","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Inutsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikiko","family":"Hashisako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taishi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Tsuchiya-Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirono","family":"Tsutsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Nakagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Mashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Shibahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Otsubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuto","family":"Yoneshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinao","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isamu","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"2493_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2493_CR2","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1111\/cas.12996","volume":"107","author":"Y Kobayashi","year":"2016","unstructured":"Kobayashi Y, Mitsudomi T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy. Cancer Sci. 2016;107:1179\u201386.","journal-title":"Cancer Sci"},{"key":"2493_CR3","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1038\/onc.2009.198","volume":"28","author":"A Gazdar","year":"2009","unstructured":"Gazdar A. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009;28:S24\u201331.","journal-title":"Oncogene"},{"key":"2493_CR4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"J-C Soria","year":"2018","unstructured":"Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer. N Engl J Med. 2018;378:113\u201325.","journal-title":"N Engl J Med"},{"key":"2493_CR5","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1093\/annonc\/mdv319","volume":"26","author":"D Planchard","year":"2015","unstructured":"Planchard D, Loriot Y, Andre F, Gobert A, Auger N, Lacroix L, et al. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann Oncol. 2015;26:2073\u20138.","journal-title":"Ann Oncol"},{"key":"2493_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08074-0","volume":"10","author":"H Taniguchi","year":"2019","unstructured":"Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, et al. AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. Nat Commun. 2019;10:259.","journal-title":"Nat Commun"},{"key":"2493_CR7","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jtho.2016.11.2231","volume":"12","author":"CC Ho","year":"2017","unstructured":"Ho CC, Liao WY, Lin CA, Shih JY, Yu CJ, Yang JC. Acquired BRAF V600E mutation as resistant mechanism after treatment with osimertinib. J Thorac Oncol. 2017;12:567\u201372.","journal-title":"J Thorac Oncol"},{"key":"2493_CR8","doi-asserted-by":"crossref","unstructured":"Piper-Vallillo AJ, Sequist LV, Piotrowska Z. Emerging treatment paradigms for EGFR-Mutant lung cancers progressing on osimertinib: A review. J Clin Oncol. 2020;38:2926\u201336.","DOI":"10.1200\/JCO.19.03123"},{"key":"2493_CR9","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","volume":"121","author":"A Leonetti","year":"2019","unstructured":"Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121:725\u201337.","journal-title":"Br J Cancer"},{"key":"2493_CR10","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jtho.2022.12.003","volume":"18","author":"N Moghal","year":"2023","unstructured":"Moghal N, Li Q, Stewart EL, Navab R, Mikubo M, D\u2019Arcangelo E, et al. Single-cell analysis reveals transcriptomic features of drug-tolerant persisters and stromal adaptation in a patient-derived EGFR-mutated lung adenocarcinoma xenograft model. J Thorac Oncol. 2023;18:499\u2013515.","journal-title":"J Thorac Oncol"},{"key":"2493_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104200","volume":"83","author":"Y Sun","year":"2022","unstructured":"Sun Y, Dong Y, Liu X, Zhang Y, Bai H, Duan J, et al. Blockade of STAT3\/IL-4 overcomes EGFR T790M-cis-L792F-induced resistance to osimertinib via suppressing M2 macrophages polarization. EBioMedicine. 2022;83:104200.","journal-title":"EBioMedicine"},{"key":"2493_CR12","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1038\/s41388-019-1099-5","volume":"39","author":"J Huang","year":"2020","unstructured":"Huang J, Lan X, Wang T, Lu H, Cao M, Yan S, et al. Targeting the IL-1beta\/EHD1\/TUBB3 axis overcomes resistance to EGFR-TKI in NSCLC. Oncogene. 2020;39:1739\u201355.","journal-title":"Oncogene"},{"key":"2493_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-022-02509-x","volume":"22","author":"X Wan","year":"2022","unstructured":"Wan X, Xie B, Sun H, Gu W, Wang C, Deng Q, et al. Exosomes derived from M2 type tumor-associated macrophages promote osimertinib resistance in non-small cell lung cancer through MSTRG.292666.16-miR-6836-5p-MAPK8IP3 axis. Cancer Cell Int. 2022;22:83.","journal-title":"Cancer Cell Int"},{"key":"2493_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09877-7","volume":"22","author":"H Feng","year":"2022","unstructured":"Feng H, Cao B, Peng X, Wei Q. Cancer-associated fibroblasts strengthen cell proliferation and EGFR TKIs resistance through aryl hydrocarbon receptor dependent signals in non-small cell lung cancer. BMC Cancer. 2022;22:764.","journal-title":"BMC Cancer"},{"key":"2493_CR15","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1172\/JCI96148","volume":"128","author":"K Gong","year":"2018","unstructured":"Gong K, Guo G, Gerber DE, Gao B, Peyton M, Huang C, et al. TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. J Clin Invest. 2018;128:2500\u201318.","journal-title":"J Clin Invest"},{"key":"2493_CR16","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/s43018-020-0048-0","volume":"1","author":"K Gong","year":"2020","unstructured":"Gong K, Guo G, Panchani N, Bender ME, Gerber DE, Minna JD, et al. EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer. Nat Cancer. 2020;1:394\u2013409.","journal-title":"Nat Cancer"},{"key":"2493_CR17","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41698-024-00557-2","volume":"8","author":"R Ibusuki","year":"2024","unstructured":"Ibusuki R, Iwama E, Shimauchi A, Tsutsumi H, Yoneshima Y, Tanaka K, Okamoto I. TP53 gain-of-function mutations promote osimertinib resistance via TNF-alpha-NF-kappaB signaling in EGFR-mutated lung cancer. NPJ Precis Oncol. 2024;8:60.","journal-title":"NPJ Precis Oncol"},{"key":"2493_CR18","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1158\/1078-0432.CCR-22-3379","volume":"29","author":"SA Patel","year":"2023","unstructured":"Patel SA, Nilsson MB, Yang Y, Le X, Tran HT, Elamin YY, et al. IL6 mediates suppression of T- and NK-cell function in EMT-associated TKI-resistant EGFR-mutant NSCLC. Clin Cancer Res. 2023;29:1292\u2013304.","journal-title":"Clin Cancer Res"},{"key":"2493_CR19","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.21037\/tlcr-22-393","volume":"11","author":"R Ibusuki","year":"2022","unstructured":"Ibusuki R, Yoneshima Y, Hashisako M, Matsuo N, Harada T, Tsuchiya-Kawano Y, et al. Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1\/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer. Transl Lung Cancer Res. 2022;11:2208\u201315.","journal-title":"Transl Lung Cancer Res"},{"key":"2493_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10:1523.","journal-title":"Nat Commun"},{"key":"2493_CR21","doi-asserted-by":"crossref","unstructured":"Nakamura S, Shibahara D, Tanaka K, Kishikawa Y, Hashisako M, Nakatomi K, Nakagaki N, Kohno M, Azuma K, Ibusuki R et al. Spatial dynamics of the tumor microenvironment in emerging resistance to targeted therapy in EGFR-mutated NSCLC. Preprint at https:\/\/www.biorxivorg\/content\/101101\/20250210637543v1\u00a0.2025.","DOI":"10.1101\/2025.02.10.637543"},{"key":"2493_CR22","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","volume":"569","author":"M Ghandi","year":"2019","unstructured":"Ghandi M, Huang FW, Jane-Valbuena J, Kryukov GV, Lo CC, McDonald ER 3rd, Barretina J, Gelfand ET, Bielski CM, Li H, et al. Next-generation characterization of the cancer cell line encyclopedia. Nature. 2019;569:503\u20138.","journal-title":"Nature"},{"key":"2493_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002909","author":"CC Bailey","year":"2012","unstructured":"Bailey CC, Huang I-C, Kam C, Farzan M. Ifitm3 limits the severity of acute influenza in mice. PLoS Pathog. 2012. https:\/\/doi.org\/10.1371\/journal.ppat.1002909.","journal-title":"PLoS Pathog"},{"key":"2493_CR24","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/0092-8674(84)90270-8","volume":"38","author":"RL Friedman","year":"1984","unstructured":"Friedman RL, Manly SP, McMahon M, Kerr IM, Stark GR. Transcriptional and posttranscriptional regulation of interferon-induced gene expression in human cells. Cell. 1984;38:745\u201355.","journal-title":"Cell"},{"key":"2493_CR25","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41586-020-2884-6","volume":"588","author":"J Lee","year":"2020","unstructured":"Lee J, Robinson ME, Ma N, Artadji D, Ahmed MA, Xiao G, et al. IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cells. Nature. 2020;588:491\u20137.","journal-title":"Nature"},{"key":"2493_CR26","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nature10921","volume":"484","author":"AR Everitt","year":"2012","unstructured":"Everitt AR, Clare S, Pertel T, John SP, Wash RS, Smith SE, et al. IFITM3 restricts the morbidity and mortality associated with influenza. Nature. 2012;484:519\u201323.","journal-title":"Nature"},{"key":"2493_CR27","doi-asserted-by":"publisher","first-page":"8780","DOI":"10.1128\/JVI.00655-16","volume":"90","author":"S Poddar","year":"2016","unstructured":"Poddar S, Hyde JL, Gorman MJ, Farzan M, Diamond MS. The Interferon-Stimulated gene IFITM3 restricts infection and pathogenesis of arthritogenic and encephalitic alphaviruses. J Virol. 2016;90:8780\u201394.","journal-title":"J Virol"},{"key":"2493_CR28","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41586-020-2681-2","volume":"586","author":"JY Hur","year":"2020","unstructured":"Hur JY, Frost GR, Wu X, Crump C, Pan SJ, Wong E, Barros M, Li T, Nie P, Zhai Y, et al. The innate immunity protein IFITM3 modulates gamma-secretase in alzheimer\u2019s disease. Nature. 2020;586:735\u201340.","journal-title":"Nature"},{"key":"2493_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06416-5","volume":"15","author":"Z Xiong","year":"2024","unstructured":"Xiong Z, Xu X, Zhang Y, Ma C, Hou C, You Z, et al. IFITM3 promotes glioblastoma stem cell-mediated angiogenesis via regulating JAK\/STAT3\/bFGF signaling pathway. Cell Death Dis. 2024;15:45.","journal-title":"Cell Death Dis"},{"key":"2493_CR30","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41419-019-1750-7","volume":"10","author":"X Liu","year":"2019","unstructured":"Liu X, Chen L, Fan Y, Hong Y, Yang X, Li Y, Lu J, Lv J, Pan X, Qu F, et al. IFITM3 promotes bone metastasis of prostate cancer cells by mediating activation of the TGF-beta signaling pathway. Cell Death Dis. 2019;10:517.","journal-title":"Cell Death Dis"},{"key":"2493_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-022-00858-8","volume":"12","author":"P-Y Chu","year":"2022","unstructured":"Chu P-Y, Huang W-C, Tung S-L, Tsai C-Y, Chen CJ, Liu Y-C, et al. IFITM3 promotes malignant progression, cancer stemness and chemoresistance of gastric cancer by targeting MET\/AKT\/FOXO3\/c-MYC axis. Cell Biosci. 2022;12:124.","journal-title":"Cell Biosci"},{"key":"2493_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-018-0777-1","volume":"17","author":"S-G Wu","year":"2018","unstructured":"Wu S-G, Shih J-Y. Management of acquired resistance to EGFR TKI\u2013targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018;17:1\u201314.","journal-title":"Mol Cancer"},{"key":"2493_CR33","doi-asserted-by":"publisher","DOI":"10.1172\/JCI160330","author":"S Wang","year":"2023","unstructured":"Wang S, Rong R, Yang DM, Fujimoto J, Bishop JA, Yan S, et al. Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer. J Clin Invest. 2023. https:\/\/doi.org\/10.1172\/JCI160330.","journal-title":"J Clin Invest"},{"key":"2493_CR34","doi-asserted-by":"publisher","first-page":"112919","DOI":"10.1016\/j.ejca.2023.05.007","volume":"189","author":"R Han","year":"2023","unstructured":"Han R, Guo H, Shi J, Wang H, Zhao S, Jia Y, Liu X, Li J, Cheng L, Zhao C, et al. Tumour microenvironment changes after osimertinib treatment resistance in non-small cell lung cancer. Eur J Cancer. 2023;189:112919.","journal-title":"Eur J Cancer"},{"key":"2493_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao4307","volume":"9","author":"MB Nilsson","year":"2017","unstructured":"Nilsson MB, Sun H, Diao L, Tong P, Liu D, Li L, et al. Stress hormones promote EGFR inhibitor resistance in NSCLC: implications for combinations with \u03b2-blockers. Sci Transl Med. 2017;9:eaao4307.","journal-title":"Sci Transl Med"},{"key":"2493_CR36","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1158\/1078-0432.CCR-13-2613","volume":"20","author":"L Li","year":"2014","unstructured":"Li L, Han R, Xiao H, Lin C, Wang Y, Liu H, et al. Metformin sensitizes EGFR-TKI\u2013resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. Clin Cancer Res. 2014;20:2714\u201326.","journal-title":"Clin Cancer Res"},{"key":"2493_CR37","doi-asserted-by":"publisher","first-page":"15535","DOI":"10.1073\/pnas.1009472107","volume":"107","author":"Z Yao","year":"2010","unstructured":"Yao Z, Fenoglio S, Gao DC, Camiolo M, Stiles B, Lindsted T, et al. TGF-\u03b2 IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci U S A. 2010;107:15535\u201340.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2493_CR38","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41467-017-00450-6","volume":"8","author":"K Jacobsen","year":"2017","unstructured":"Jacobsen K, Bertran-Alamillo J, Molina MA, Teixido C, Karachaliou N, Pedersen MH, Castellvi J, Garzon M, Codony-Servat C, Codony-Servat J, et al. Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. Nat Commun. 2017;8:410.","journal-title":"Nat Commun"},{"key":"2493_CR39","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1097\/JTO.0000000000000688","volume":"10","author":"TM Kim","year":"2015","unstructured":"Kim TM, Song A, Kim D-W, Kim S, Ahn Y-O, Keam B, et al. Mechanisms of acquired resistance to AZD9291: a mutation-selective, irreversible EGFR inhibitor. J Thorac Oncol. 2015;10:1736\u201344.","journal-title":"J Thorac Oncol"},{"key":"2493_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00208-w","volume":"5","author":"MG Terp","year":"2021","unstructured":"Terp MG, Jacobsen K, Molina MA, Karachaliou N, Beck HC, Bertran-Alamillo J, et al. Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells. NPJ Precis Oncol. 2021;5:65.","journal-title":"NPJ Precis Oncol"},{"key":"2493_CR41","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/35052073","volume":"2","author":"Y Yarden","year":"2001","unstructured":"Yarden Y, Sliwkowski MX. Untangling the erbb signalling network. Nat Rev Mol Cell Biol. 2001;2:127\u201337.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2493_CR42","doi-asserted-by":"publisher","first-page":"ra50","DOI":"10.1126\/scisignal.2002581","volume":"5","author":"M Yamashita","year":"2012","unstructured":"Yamashita M, Chattopadhyay S, Fensterl V, Saikia P, Wetzel JL, Sen GC. Epidermal growth factor receptor is essential for Toll-like receptor 3 signaling. Sci Signal. 2012;5:ra50\u201350.","journal-title":"Sci Signal"},{"key":"2493_CR43","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/nri1900","volume":"6","author":"K Honda","year":"2006","unstructured":"Honda K, Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol. 2006;6:644\u201358.","journal-title":"Nat Rev Immunol"},{"key":"2493_CR44","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/j.1432-1033.1991.tb16139.x","volume":"199","author":"AR Lewin","year":"1991","unstructured":"Lewin AR, Reid LE, McMAHON M, Stark GR, Kerr IM. Molecular analysis of a human interferon-inducible gene family. Eur J Biochem. 1991;199:417\u201323.","journal-title":"Eur J Biochem"},{"key":"2493_CR45","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1146\/annurev-immunol-032713-120231","volume":"32","author":"WM Schneider","year":"2014","unstructured":"Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol. 2014;32:513\u201345.","journal-title":"Annu Rev Immunol"},{"key":"2493_CR46","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1141478","volume":"316","author":"JA Engelman","year":"2007","unstructured":"Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039\u201343.","journal-title":"Science"},{"key":"2493_CR47","doi-asserted-by":"publisher","first-page":"9479","DOI":"10.1158\/0008-5472.CAN-08-1643","volume":"68","author":"S Yano","year":"2008","unstructured":"Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor\u2013activating mutations. Cancer Res. 2008;68:9479\u201387.","journal-title":"Cancer Res"},{"key":"2493_CR48","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","volume":"19","author":"HA Yu","year":"2013","unstructured":"Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:2240\u20137.","journal-title":"Clin Cancer Res"},{"key":"2493_CR49","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41416-023-02475-9","volume":"130","author":"A Leonetti","year":"2024","unstructured":"Leonetti A, Verze M, Minari R, Perrone F, Gnetti L, Bordi P, et al. Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies. Br J Cancer. 2024;130:135\u201342.","journal-title":"Br J Cancer"},{"key":"2493_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35961-y","volume":"14","author":"J Chmielecki","year":"2023","unstructured":"Chmielecki J, Gray JE, Cheng Y, Ohe Y, Imamura F, Cho BC, et al. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nat Commun. 2023;14:1070.","journal-title":"Nat Commun"},{"key":"2493_CR51","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.1158\/0008-5472.CAN-11-3720","volume":"72","author":"L Xu","year":"2012","unstructured":"Xu L, Kikuchi E, Xu C, Ebi H, Ercan D, Cheng KA, et al. Combined EGFR\/MET or EGFR\/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. Cancer Res. 2012;72:3302\u201311.","journal-title":"Cancer Res"},{"key":"2493_CR52","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S1470-2045(19)30785-5","volume":"21","author":"LV Sequist","year":"2020","unstructured":"Sequist LV, Han JY, Ahn MJ, Cho BC, Yu H, Kim SW, Yang JC, Lee JS, Su WC, Kowalski D, et al. Osimertinib plus Savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020;21:373\u201386.","journal-title":"Lancet Oncol"},{"key":"2493_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.02.020","volume":"12","author":"ER York","year":"2017","unstructured":"York ER, Varella-Garcia M, Bang TJ, Aisner DL, Camidge DR. Tolerable and effective combination of full-dose Crizotinib and osimertinib targeting MET amplification sequentially emerging after T790M positivity in EGFR-mutant non-small cell lung cancer. J Thorac Oncol. 2017;12:e85\u20138.","journal-title":"J Thorac Oncol"},{"key":"2493_CR54","doi-asserted-by":"publisher","first-page":"e83-85","DOI":"10.1016\/j.jtho.2016.02.021","volume":"11","author":"JF Gainor","year":"2016","unstructured":"Gainor JF, Niederst MJ, Lennerz JK, Dagogo-Jack I, Stevens S, Shaw AT, Sequist LV, Engelman JA: Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification. J Thorac Oncol 2016, 11:e83-85.","journal-title":"J Thorac Oncol"},{"key":"2493_CR55","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1158\/2159-8290.CD-18-1022","volume":"8","author":"Z Piotrowska","year":"2018","unstructured":"Piotrowska Z, Isozaki H, Lennerz JK, Gainor JF, Lennes IT, Zhu VW, Marcoux N, Banwait MK, Digumarthy SR, Su W: Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion. Cancer discovery 2018, 8:1529-1539.","journal-title":"Cancer discovery"},{"key":"2493_CR56","doi-asserted-by":"crossref","unstructured":"Cho BC, Lu S, Felip E, Spira AI, Girard N, Lee JS, Lee SH, Ostapenko Y, Danchaivijitr P, Liu B, et al. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. N Engl J Med. 2024;391:1486\u201398.","DOI":"10.1056\/NEJMoa2403614"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02493-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02493-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02493-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T01:04:39Z","timestamp":1761699879000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-025-02493-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2493"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02493-6","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]},"assertion":[{"value":"25 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The analysis of clinical specimens in this study was approved by the ethics committee of Kyushu University Hospital (approval no. 23220-00; approval date, 6 October 2023) and was performed in accordance with the Declaration of Helsinki (as revised in 2013). Informed consent was obtained from the participating patients. Animal experiments were approved by the Kyushu University Animal Experiment Committee (approval no. A24-314-0) and were performed in accordance with Kyushu University Animal Experiment Regulations, related laws and regulations, and ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"E.I. has received honoraria from AstraZeneca and Chugai Pharmaceutical. Y.T.-K. has received personal fees from Bristol-Myers Squibb, Taiho Pharmaceutical, Chugai Pharmaceutical, AstraZeneca, Kyowa Hakko Kirin, MSD, Ono Pharmaceutical, and Takeda Pharmaceutical outside the submitted work. D.S. has received honoraria from Eli Lilly Japan K.K. Y.Y. has received honoraria from AstraZeneca. K.T. has received honoraria from Chugai Pharmaceutical, AstraZeneca, Ono Pharmaceutical, Bristol-Myers Squibb, Eli Lilly, Takeda Pharmaceutical, Novartis Pharma K.K., Merck Biopharma, Kyowa Kirin, Daiichi-Sankyo, Pfizer, Amgen, Janssen Pharmaceutical K.K., and MSD, and is an advisory board member for Pfizer and Novartis Pharma K.K. I.O. has received honoraria and research funding from Daiichi Sankyo, Chugai Pharmaceutical, Eli Lilly Japan K.K., AstraZeneca, Taiho Pharmaceutical, Boehringer Ingelheim, and Ono Pharmaceutical; honoraria from Takeda Pharmaceutical and Novartis Pharma K.K.; and research funding from Bristol-Meyers Squibb and MSD Oncology. All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"272"}}